SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vertex Pharmaceuticals Incorporated - VRTX

NEW YORK, June 3, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (NASDAQ: VRTX) Investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 237.

The investigation concerns whether Vertex and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On May 29, 2012, Vertex conceded that the previously reported exceptional results of the Phase 2 study of the two medications, VX-809 and Kalydeco, two products the Company had under development, were materially overstated.

On this news, shares of Vertex fell $7.05, or more than 10.87%, on intraday trading to a price of $57.80 on May 29, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

SOURCE Pomerantz LLP